

PATIENT BENEFITS AND COSTS ASSOCIATED WITH DIFFERENTIATED MODELS OF SERVICE DELIVERY FOR HIV TREATMENT IN SUB-SAHARAN AFRICA

AMBIT Project Report Number 01

September 3, 2019 (version 1.1)

Salome Kuchukhidze, Lawrence Long, Sophie Pascoe, Amy Huber, Brooke Nichols, Matthew Fox, Sydney Rosen

> Department of Global Health Boston University School of Public Health Boston, MA, USA

Health Economics and Epidemiology Research Office (HE²RO) Wits Health Consortium, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand Johannesburg, South Africa

For further information, contact:

Salome Kuchukhidze, skuchukh@bu.edu



INTRODUCTION

As of December 2018, 16.4 million people were reported to be receiving antiretroviral therapy (ART) for HIV in sub-Saharan Africa.¹ To achieve global "90-90-90" targets for HIV diagnosis, treatment, and viral suppression, another three million patients must be added to national HIV treatment programs during the coming decade in eastern and southern Africa.¹ At the same time, donor funding for HIV has plateaued, leading to calls for greater efficiency in service delivery.²

One response to this challenge is the development of "differentiated service delivery models" (DSD models) for HIV treatment. DSD models, which typically reduce clinic visits and/or move services out of the clinic, aim to improve clinical outcomes of treatment, such as retention in care and viral suppression; make treatment more patient-centric by lessening the burden of frequent clinic visits; and reduce costs to both the healthcare system and to patients.

Costs and benefits of DSDs to patients themselves (as opposed to costs and benefits to providers and funders) are often omitted from evaluations of specific models of service delivery and from mathematical modeling of potential impact. As part of a larger rapid review of the published and gray literature on the outcomes of DSDs since 2016, in this report we present and discuss the subset of sources that provide empirical information on patient costs and benefits and the acceptability of DSDs to patients.

METHODS

Methods for the rapid review of published sources followed those recommended by the WHO, with protocol registration in PROSPERO.³ Inclusion/ exclusion criteria and search terms are shown in Appendix 1. For review of the gray (unpublished) literature, we included poster and slide presentations and institutional (government, partner, project) reports, identified by screening websites of DSD implementing partners, government ministries of health, and research organizations.⁴ The systematic review search included articles published January 1, 2016-November 30, 2018. The gray literature search included reports published January 1, 2016-June 21, 2019.

One of the challenging aspects of the review was a lack of a consistent definition of what constitutes a DSD model of ART provision. For both systematic and gray literature reviews we adopted an approach proposed by Grimsrud and Duncombe which specifies that models can be differentiated by provider (which cadres provide care?), location (is care provided in the clinic/off-site?), frequency (how often does the patient interact with the healthcare system?), and intensity (what services are provided in the model?).^{5,6}

In the literature review, costs and benefits included:

- Costs, defined to include differences in monetary and in-kind resource usage from the patient perspective. Costs included monetary payment for travel and service, value of wages lost, and time spent traveling, waiting for, and/or receiving services. Cost savings (e.g. a reduction in transport fares paid) are reflected as negative costs.
- Benefits and drawbacks, or self-reported positive and negative aspects of DSD participation (facilitators and barriers). Benefits are reported per model category as opposed to per model/source document to avoid repetition.
- Satisfaction, a self-reported measure of patient satisfaction with services.
- Preferences, meaning patients' preferences for being enrolled in a DSD model compared to the traditional or standard of care (SOC) model.

We categorized the models using the taxonomy proposed by Grimsrud and colleagues.⁶

- Facility based individual models (FBIMs) are models that provide one-to-one HIV services at the healthcare facility (e.g. Multi-Month Scripting, Facility Fast Track, Enhanced Adherence Counseling)
- Out-of-facility based individual models (OFBIMs) provide care in the community to each individual patient (e.g. Home ART delivery, Decentralized Medication Delivery, Mobile Clinics).
- Healthcare worker led groups (HCWLGs), are a group model typically supported by a clinically trained healthcare worker or a lay health worker (e.g. Adherence Clubs, Teen Clubs)
- Client led groups (CLGs) are a group model that provides services either in the community or at the facility and are led by patients (Community Adherence Groups, Urban Adherence Groups).

Our data extraction tool captured unique differentiated service delivery models as separate entries regardless of whether the source documents reported one or many models. The tables below report results per individual model.

RESULTS

The two reviews identified 54 publications (journal papers and peer-reviewed abstracts) and 34 reports and other unpublished documents that met inclusion criteria. Among these, 29 documents, from 11 countries (Figure 1) reported one or more costs or benefits to patients and are included in this sub-review. A list of sources, by model category and country, can be found in Appendix 2. Below we summarize results for each type of cost or benefit, by model category, and report individual results in the tables. The number of estimates for each category was generally quite small, making generalization difficult. Equally limiting is that many documents did not provide any comparative information, but simply reported outcomes for the DSD model(s). We cannot know how DSD models compared to standard of care for these models. In the tables, we list the results with comparative information first, then those without comparisons.




Figure 1. Countries with reports of patients' benefits and costs of DSD models

COSTS

Costs for travel and time are reported in Table 1. In Malawi, all the models studied by Prust et al. (2017) reduced both travel costs and time substantially, compared to standard of care.⁷ Community ARV delivery cut travel costs in Tanzania⁸ and Youth care clubs also reduced visit time.⁹ No reports suggested that patient costs, whether for money or time, were higher than for the associated non-differentiated care.

Country	Model	DSD		SO	С
		Travel cost (USD)	Time or	Travel cost (USD)	Time or
			distance		distance
Facility based indi	vidual models				
Malawi	Fast track refills ^{7**}	\$2.30/year	20.9 hrs/year	\$7.00/year	74.7 hrs./year
	Multimonth scripting ⁷	\$2.30/year	24.9 hrs/year	\$7.00/year	74.7 hrs./year
Out of facility bas	ed individual models				
South Africa	Centralized chronic	\$1.07/visit	12.9% patients		
	medicines dispensing		>1 hour travel		
	and distribution		time to pickup		
	(CCMDD) ¹⁰		point		
South Africa	Community based ART	83% reduction in			
	pick-up points ¹¹	travel cost/year			
Tanzania	ARV community	\$0.40/year		\$3.30/year	
	delivery ⁸				
Uganda	Community		9.0 wait		
	pharmacies ^{12***}		hrs/year		
Healthcare worke	r led groups				
South Africa	Youth care club ^{9***}		13.8 visit		48.0 visit
South Anica	Touth care club		hrs./year		hrs./year
	Adherence club ¹⁰	\$0.80/visit	20% of patients		
			> 1 hour travel		
			time from AC		
			meeting point		
Client led groups					
Malawi	Community ART group	\$1.20/year	36.8 hrs/year	\$7.00/year	74.7 hrs./year
	(CAG) ⁷				

*Monetary costs were converted into USD using the annual average exchange rate for the local currency over the last data year.

** Patients enrolled in FTR and receiving MMS.

***Assumed minimum frequency to annualize.

BENEFITS AND DRAWBACKS

Patients identified a wide range of potential advantages and disadvantages to DSD models, as shown in Table 2.

Table 2. Patient reported benefits and	drawbacks to DSD participation
--	--------------------------------

Model category		
Facility based individual models	 Reduced waiting time^{13,14} Facility decongestion^{13,15} Reduced travel cost^{13,14} More patient freedom for employment and family travel¹⁶ Potential for improved adherence and retention¹⁷ No reports of unwanted disclosure¹⁶ Patients successfully carried large supply of ARVs¹⁶ Patients successfully stored drugs for a long time¹⁶ No problems with lost or stolen medications¹⁶ 	 Concerns regarding safety and storage of medication for a long period of time at home for models that include multi-month dispensation¹⁸ Drug stock-outs and supply chain issues^{13,15} Inconsistent implementation across facilities¹³ Long wait times during clinic visits¹⁹ Some concerns about stigma¹⁶
Out of facility based individual models	 Benefits for female sex workers (FSW)²⁰ Reduced waiting time Reduced transport cost Minimizes sex work-related stigma and risks or inadvertent status disclosure. Provides a safety net for FSW who have missed ART pickup Improves tracing of FSW 	 Patient fear of stigmatization^{14,20} FSWs are concerned about the branding of mobile clinics which may lead to accidental HIV disclosure^{14,20}
Healthcare worker led groups	 Provides a group identity/peer support²¹ Empowers patients to stay adherent and rema in care²¹ Less time consuming (short queues)²² More convenient for employed patients²³ Reduces stigma²⁴ Helps link patient to care and track LTFU²⁵ 	 May lead to complicated patient-provider relations²⁶ Patient concern about big group size, stigma, and unintended disclosure of status²⁴ Patient concern about needing to find members to join the group²⁷ Patient concern about models being time consuming and inefficient²⁸ Patient concern about ARTs not delivered in time²⁸
Client led groups	 Improved social support¹³ Savings in transport costs²⁹ More patient freedom to engage in employme and family activities²⁹ 	Privacy and confidentiality concerns (fear of accidental disclosure) ^{13,29}

SATISFACTION AND PREFERENCES


Several studies reported patients' satisfaction with models of service delivery, as shown in Table 3. For all models, satisfaction with care was high (>81%) (Figure 3; Table 3). No comparative data were reported to indicate whether patient satisfaction with DSD models was higher than with standard of care, however. Group models were less preferred than individual models, in general.

Table 3. Patient satisfaction with and	preference for DSD models
--	---------------------------

Country	Model name	Satisfaction metric or model to which DSD is preferred	% of patients reporting satisfaction with DSD model	% of patients reporting that they prefer the DSD model
Facility based	individual models			
Tanzania	Clinic and home based adherence intervention ³¹	% patients who were "satisfied" or "very satisfied" with care	97.6%	
South Africa	Fast track initiation counselling ¹⁰	% patients rating care as "good" or "very good"	81.9%	
South Africa	Tracing for retention in care ¹⁰	% patients rating tracer to be "good" or "very good" in terms of respect	85.7%	
Kenya	Facility fast track ³²	Compared to CAG		84.7%
•	based individual models		00.004	
South Africa	Centralized chronic medicines dispensing and distribution ¹⁰	% patients who were happy to be enrolled in model	96.3%	
Tanzania	ARV community delivery ³³	% patients who were "satisfied" or "very satisfied" with ARV community delivery	96.9%	
Ghana	Refills from community based case managers for key populations ³⁴	Compared to refills by clinicians		80.0% [§]
Mozambique	Community pharmacies ³⁵	Compared to SOC		84.0%
Tanzania	Home-based delivery ³⁶	Compared to SOC		86.0%
Uganda	Community-based ART ³⁷	Compared to SOC		87.4%
Zambia	Home-based delivery ³⁸	Compared to adherence club or SOC		70.5%
Healthcare wo	orker led groups			
South Africa	Adherence clubs ¹⁰	% patients who were "satisfied" or "very satisfied" with care	96.3%	
Zambia	Adherence clubs ³⁸	Compared to home-based delivery or SOC		15.4%
Client led grou	ıps	·		
Kenya	Community adherence groups ³²	Compared to facility fast track		15.3%
Zambia	Community adherence groups ³⁰	Compared to SOC		64.2%

§ Preferred refills from case managers, family members, or non-clinicians.

Figure 3. Patient satisfaction with DSD models



A small handful of studies reported patients' preferences for specific model of service delivery (Table 3; Figure 4). As shown in Figure 4 large majority of patients expressed a preference for individual models, whether at or out of a facility. Group models (adherence clubs, CAGs) were less popular.




Figure 4. Patient preferences for models of ART delivery compared to other DSD models or the SOC

¥Models where preference was expressed in comparison to one or more DSD models. Further detail on which model DSD is preferred to is listed in Table 3.

INTERPRETATION

As the tables and figures above reveal, information available about the costs and benefits of DSD to patients is scarce, and there is tremendous heterogeneity in the metrics and definitions used to capture the information that is available. Although we can propose a few general conclusions from this review of a subset of the recent literature on DSD, it is important to bear in mind that each is drawn from only a very small number of reports, giving us limited generalizability.

- In the three instances where comparative data on standard of care are reported, DSD saved patients substantial amounts of money on travel costs and greatly reduced the time required to receive ART, including time spent on transport, waiting in the queue, or having a clinic visit. There were no reports of DSD models that increased patient financial or time costs, though there is a strong likelihood of publication bias for this indicator (i.e. DSD that were found to impose additional costs on patients might not have been reported in the literature).
- Most non-quantitative reports of benefits and drawbacks cited reduced costs (both financial and time costs, often with mention of employment) among their main advantages, along with model category-specific benefits such as social support arising from group models. The main drawbacks identified were accidental HIV status disclosure and logistical concerns about how the models operated.
- Satisfaction with DSDs was very high, in all reports exceeding 80% of patients. Like costs, we expect that there is some publication bias for this indicator (i.e. DSD that were not satisfactory were not reported in the literature).
- Finally, when choosing between group models (CLG) and individual models of care (FBIM), most patients preferred the latter. When given a choice between a DSD and the standard of care, however, most (>80%) preferred a DSD model.

We also conclude that:

- There is insufficient evidence to make broad generalizations about which models are "better" or "worse" for patients. It is almost certain that perceptions of benefits and costs vary by individual patient, by facility or program, and by setting. There is also little or no information about patient preferences for one DSD model over another, as head-to-head comparisons in which patients were free to choose which model to enter are non-existent.
- None of the studies reported here linked patient satisfaction (or other costs or benefits) with clinical outcomes. Hypothetically, lower costs or larger benefits for patients should improve retention in care and viral suppression rates, but there is no evidence to support whether or not the modest clinical outcome improvements described for some DSD models are in any way related to non-clinical consequences such as lower costs.
- As with other DSD research, definitions and metrics for assessing types of costs and benefits and levels of satisfaction are inconsistent across studies, and some are difficult to interpret. Estimating savings in travel costs per clinic visit, for example, is not very meaningful without empirical data on numbers of visits.
- Finally, we note that many DSD interventions' patient-level benefits and costs were described without any comparison values, either to the standard of care or to another model. Studies that report that a high proportion of patients were satisfied with a DSD model, for example, generally do not tell us what proportion were also satisfied with the standard of care. Since most models enroll only experienced, clinically stable ART patients who, by definition, have already overcome most obstacles to standard of care, it is possible that many of them would be satisfied either way.

REFERENCES

- 1. UNAIDS. UNAIDS Data 2018 [Internet]. 2018. Available from: https://www.unaids.org/sites/default/files/media_asset/unaids-data-2018 en.pdf
- 2. Barker C, Dutta A, Klein K. Can differentiated care models solve the crisis in HIV treatment financing? Analysis of prospects for 38 countries in sub-Saharan Africa. J Int AIDS Soc. 2017;20(Suppl 4):21648.
- Tricco AC, Langlois E V, Straus SE. Rapid reviews to Strengthen Health Policy and Systems: A practical Guide [Internet]. 2017. Available from: https://apps.who.int/iris/bitstream/handle/10665/258698/9789241512763eng.pdf;jsessionid=55EF1F06DB9939A5B8EF40E8A633EB7C?sequence=1
- 4. Godin K, Stapleton J, Kirkpatrick SI, Hanning RM, Leatherdale ST. Applying systematic review search methods to the grey literature: A case study examining guidelines for school-based breakfast programs in Canada. Syst Rev. 2015;4(1):1–10.
- Duncombe C, Rosenblum S, Hellmann N, Holmes C, Wilkinson L, Biot M, et al. Reframing HIV care: Putting people at the centre of antiretroviral delivery. Vol. 20, Tropical Medicine and International Health. Blackwell Publishing Ltd; 2015. p. 430– 47.
- 6. Grimsrud A, Barnabas R V., Ehrenkranz P, Ford N. Evidence for scale up: The differentiated care research agenda. Vol. 20, Journal of the International AIDS Society. International AIDS Society; 2017.
- 7. Prust ML, Banda CK, Nyirenda R, Chimbwandira F, Kalua T, Jahn A, et al. Multi-month prescriptions, fast-track refills, and community ART groups: Results from a process evaluation in Malawi on using differentiated models of care to achieve national HIV treatment goals. J Int AIDS Soc. 2017;20:41–50.
- 8. Geldsetzer P, Francis JM, Sando D, Asmus G, Lema IA, Mboggo E, et al. Community delivery of antiretroviral drugs: A noninferiority cluster-randomized pragmatic trial in Dar es Salaam, Tanzania. PLoS Med. 2018 Sep 1;15(9).
- 9. Pahad S, Beery M, Martin CE, Henwood R, Dondolo E, Ngobeni M, et al. Youth Care Clubs: Optimising clinic time, fostering peer support, improving adherence [Internet]. 2018. Available from: https://www.sahivsoc2018.co.za/wp-content/uploads/2018/11/22C_Moira-Beery.pdf
- National Department of Health. Evaluation of the National Adherence Guidelines for chronic diseases in South Africa: patient perspectives on differentiated care models [Internet]. Washington D.C.; 2017. Available from: http://documents.worldbank.org/curated/en/779941507667444415/pdf/120344-WP-PUBLIC-85p-add-series-SAProcessEvaluationPatientReportFINAL.pdf
- 11. Roberts P. Community Based ART Pick-up Points. 2018; Available from: http://cquin.icap.columbia.edu/wp-content/uploads/2018/03/Roberts_CCMDD_Final.pdf
- 12. Ssuuna M, Nakade S, Zalwango S, Mubiru J, Okello D, Otim L, et al. The IDI-KCCA Community Pharmacy ART Refill Program. 2018;(November):2018. Available from: http://cquin.icap.columbia.edu/wp-content/uploads/2018/11/Communitypharmacy-poster-Infectious-Diseases-Institute-2.pdf
- 13. Prust ML, Banda CK, Callahan K, Nyirenda R, Chimbwandira F, Kalua T, et al. Patient and health worker experiences of differentiated models of care for stable HIV patients in Malawi: A qualitative study. PLoS One. 2018 Jul 1;13(7).
- 14. Katchy I, Etsetowaghan A, Ibrahim S, Ogundehin D, Ezekiel J. Client and health worker perception to differentiated HIV care: A qualitative study from Kebbi State, North West Nigeria [Internet]. 2018. Available from: http://programme.aids2018.org/Abstract/Abstract/6832
- 15. Attah M, Mohammed A, Hassan S AF. Nigeria ARV multimonth scripting: Impact on public health service delivery, infrastructure and supply chain management systems across "high volume" ART clinics [Internet]. Available from: https://programme.aids2018.org/Abstract/Abstract/4350
- 16. Khumbo Nyirenda. Client and Provider Experiences withMulti-month Dispensing in Malawi and Zambia [Internet]. Available from: https://cquin.icap.columbia.edu/wp-content/uploads/2019/04/CQUIN-webinar_Ethiopia-MMS_FINAL-1.pdf
- 17. Ifeaoma K. Client and health worker perceptions of differentiated care: a qualitative study from Kebbi State,North West Nigeria [Internet]. Available from: http://programme.aids2018.org/Abstract/Abstract/6832
- 18. Assefa T, Melaku Z, Amdino W, Abebe A, Rabkin M, Hartsough K, et al. Implementation of the Appointment Spacing Model of Differentiated Service Delivery in Ethiopia: Successes and Challenges [Internet]. 2018. Available from: https://programme.aids2018.org/Abstract/Abstract/8612
- 19. Jere L, Cheelo C, Mukumbwa-Mwenechanya M MC. Health Care Works And Patients Experiences on Piloting Fast Track Model: Piloting Differentiated ART Models In Zambia [Internet]. 2018. Available from: www.aids2018.org
- 20. Comins C, Parmley L, Schwartz S, Mkhize H, Guddera V PD. Barriers and facilitators to successful decentralized treatment provision for female sex workers living with HIV in Durban, South Africa [Internet]. 2018. Available from: https://programme.aids2018.org/Abstract/Abstract/10886
- 21. Meehan A, Gunst C, Wademan D, Hoddinott G, Holtman R, Grobbelaar N, et al. Implementing community-based adherence clubs for stable ART patients in South Africa. Lessons learned from patient and health worker experiences. 2018.

- 22. Trafford Z, Gomba Y, Colvin CJ, Iyun VO, Phillips TK, Brittain K, et al. Experiences of HIV-positive postpartum women and health workers involved with community-based antiretroviral therapy adherence clubs in Cape Town, South Africa. BMC Public Health. 2018 Jul 31;18(1).
- 23. Roy M, Bolton C, Sikazwe I, Mukumbwa-Mwenechanya M, Efronson E, Somwe P, et al. Implementation and effectiveness of urban adherence clubs in Zambia [Internet]. 2018. Available from: http://programme.aids2018.org/Abstract/Print/?abstractid=12258
- 24. Mwamba C, Topp SM, Cheelo C, Jere L, Mukumbwa-Mwenechanya M, Nkwemu S, et al. Anticipated and lived experiences of stable patients on ART in Urban Adherence Groups: a qualitative study from Zambia. 2018.
- 25. HIV Service Delivery Models Mapping HIV Service Delivery Strategies in Tanzania [Internet]. 2017. Available from: https://www.go2itech.org/wp-content/uploads/2017/07/SDM_Tanzania_Mapping-Report_FINAL_June2017_-with-Signature.pdf
- 26. Trafford Z, Gomba Y, Colvin CJ, Iyun VO, Phillips TK, Brittain K, et al. Experiences of HIV-positive postpartum women and health workers involved with community-based antiretroviral therapy adherence clubs in Cape Town, South Africa. BMC Public Health. 2018 Jul;18(1):935.
- Roy M, Mpande M, Efronson E ML. Uptake and Adaptation of Community Adherence Groups in Zambia [Internet]. CROI;
 2017. Available from: http://www.croiconference.org/sessions/uptake-and-adaptation-community-adherence-groups-zambia
- 28. Berrada S. Peer Support to retain PLHIV in care Quality Assurance in community-based adherence clubs. 2019;(March). Available from: https://za.usembassy.gov/wp-content/uploads/sites/19/Peer-Support-to-Retain-PLHIV-in-Care_Stephanie-Berrada_CaSIPO.pdf
- 29. Mashungu V, Munkuli J, Khembo W, Kumani B, Nkawu B, Fatti G, et al. Acceptability of community differentiated models of care: A patient and service provider's perspective on community art refill groups in Zimbabwe [Internet]. 2018. Available from: https://programme.aids2018.org/Abstract/Abstract/11997
- 30. Mwamba D, Thulani R, Mwanza M, Herce M, Roy M, Smith H, et al. Community Adherence Groups for Virologically Unsuppressed ART-treated Patients : Early Lesson Learned from Lusaka , Zambia. 2018;49(February):2018.
- 31. McCoy SI, Fahey C, Rao A, Kapologwe N, Njau PF, Bautista-Arredondo S. Pilot study of a multi-pronged intervention using social norms and priming to improve adherence to antiretroviral therapy and retention in care among adults living with HIV in Tanzania. PLoS One. 2017 May 1;12(5).
- 32. Obunga J. Experiences and Lessons learned in implementing the Differentiated Care Model in HIV Clinics in Nyamira County [Internet]. 2018. Available from: http://programme.aids2018.org/Abstract/Abstract/9892
- 33. Geldsetzer P, Francis JM, Ulenga N, Sando D, Lema IA, Mboggo E, et al. The impact of community health worker-led home delivery of antiretroviral therapy on virological suppression: a non-inferiority cluster-randomized health systems trial in Dar es Salaam, Tanzania. BMC Health Serv Res. 2017;17(1):1–12.
- 34. Benefour S, Tapsoba T WE. Community-based HIV care and treatment: Differential care among stable key population positives in Ghana. International AIDS Society; 2018.
- 35. Maranga A, Dias. Feasibility of Improving Access to Antiretroviral Therapy through Community Pharmacies in Mozambique [Internet]. 2018. Available from: www.aids2018.org
- Francis JM, Geldsetzer P, Ulenga N, Sando D, Lema IA, Mboggo E, et al. The acceptibility and feasibility of community health worker-led home-delivery of antiretroviral theraphy: early findings from a health systems trial in Dar es Salaam [Internet].
 2017. Available from: http://www.differentiatedcare.org/Portals/0/adam/Content/eCzm5lqYiEi5NdXO0Z-Rwg/File/Homedelivery_Tanzania_Francis.pdf
- 37. Semitala FC, Atuhumuza E, Muyindike W, Sabiti L, Karirirwe G, Walusimbi S, et al. Patient's preferences for Differentiated HIV service delivery in a routine program setting in Uganda-A cross sectional survey Background [Internet]. 2018. Available from: http://programme.aids2018.org/Abstract/Print/?abstractid=2122
- 38. Limbada M, Fidler S, Macleod S, Shibwela O, Floyd S ND, V. Situmbeko, R. Hayes HA. Acceptability and preferences of two different community models of ART delivery in a high prevalence urban setting in Zambia, nested within the HPTN 071 (PopART) trial [Internet]. International AIDS Society; 2018. Available from: https://programme.aids2018.org/Abstract/Print/?abstractid=5450

APPENDIX 1: INCLUSION/EXCLUSION CRITERIA

Parameter	Inclusion criteria	Exclusion criteria
Population	All ages and sexes; confirmed HIV positive status; on any	Pregnant women in PMTCT programs;
	regimen of lifelong antiretroviral treatment	on ART for HIV prevention (PEP or PrEP)
Geographic region	Sub-Saharan Africa None	
Intervention	Delivery of lifelong ART that differs from standard or traditional care in terms of at least one of population, location, frequency, provider cadre, or services provided	Report solely about standard or traditional model for delivering ART, absent any differentiation based on population, location, frequency, provider cadre, or services provided
Required descriptive data about model	Describes all of patients, location, frequency, provider, provider cadre, and services provided (see below for further explanation of this criterion)*	Insufficient description of all the characteristics needed to define the model
Comparator	Not required; single arm evaluations are eligible	None
Outcomes	Reports at least one of coverage of population in need, uptake of ART, clinical outcomes, costs/resource utilization, acceptability to patients or providers, or feasibility of implementation	Insufficient detail provided to estimate at least one outcome
Timing	A majority of follow up data report on the delivery of antiretroviral treatment on or after January 1, 2016	A majority of follow up data report on the period before January 1, 2016
Sector	Services provided to the public sector through government-managed public health infrastructure or through NGO/private programs or facilities that serve the uninsured sector	Services or programs for privately (commercially) insured patients
Study design	Reports primary, patient-level data from retrospective or prospective cohorts collected under any study design (trial, observational) with or without a comparison group	Systematic or other reviews, case series or reports, treatment guidelines, mathematical models, editorials, commentaries

APPENDIX 2: SOURCES BY MODEL CATEGORY

Facility based individual models (FBIM) April 2017-June appointment spacing 2018 n=13,030 patients Assefa 2018 ¹⁸ Absefa 2018 ¹⁹ Absefa 2018 ¹⁸ Absefa 2018 ¹⁸ Absefa 2018 ¹⁸ Absefa 2018 ¹⁹ Absefa 2018	Country	Model name	Dates of data collection	Sample size	Author	Туре
EthiopiaSix-month appointment spacingApril 2017-June 2018n=13,030 patientsAssefa 201818AbsMalawiFast-track refills; Multi-month scriptingFeb-May 2016n=714 observations of visit 	Facility based	l individual models (FBIM				
Multi-month scriptingtime and flowMalawiFast-track refills; Multi-month scriptingFeb-May 2016 Patients $n=32$ interviews with HCW; patientsPrust 201813 Prust 201813Art Prust 201813MalawiMulti-month scriptingNov 2016-Feb 2017 Patients $n=97$ (n=62 patient data reported in this analysis) (ICAP Interval Study)16Nyirenda 2018 (CAP Interval Study)16Prust 201813NigeriaMulti-month scripting PatientsJan-Oct 2017 Patients $n=15$ KII with HCW n=6 FGD with patients. Total n≤48Attah 201813Abs Attah 201813ZambiaFacility fast trackDec 2016-Jan 2017 Patient tracing $n=32,110$ patientsJere 201813Abs PatientsTanzaniaClinic and home based adherence interventionAug 2015-Feb 2016 Nov 2016-Feb 2017 $n=31,110$ patientsObunga 201832Abs Patient tracingOut of facility bast trackJan-Sept 2017 Nov 2016-Feb 2017 $n=31,110$ patientsObunga 201832Abs Patient tracingOut of facility bast trackJan-Sept 2017 Nov 2016-Feb 2017 $n=15$ KII with HCWs $n=66$ FGD with patients Total ns48Katchy 201817 Abs Patient tracingAbs Patient tracingOut of facility baseIndividual models (OFBIM) $n=15$ KII with HCWs $n=66$ FGD with patients Total ns48Katchy 201817 Abs Patient tracingSouth AfricaCentral chronic medication deliveryNov 2016-Feb 2017 $n=24$ FSWRep Colonactive registered patientsSouth AfricaCentral chronic medication deliveryNov 2016-Feb 2017	-	Six-month	April 2017-June	n=13,030 patients	Assefa 2018 ¹⁸	Abstrac
Multi-month scriptingn=30 FGDs with 216 patientsMalawiMulti-month scriptingNov 2016-Feb 2017n=97 (n=62 patient data reported in this analysis)Nyirenda 2018 (ICAP Interval Study)16NigeriaMulti-month scriptingJan-Oct 2017n=49,680 patientsAttah 2018 ¹⁵ Abs Abs n=6 FGD with patientsNigeriaMulti-month scriptingOct-Dec 2017n=15 KII with HCW n=6 FGD with patients and professional HCW n=8 IDIs with other HCWJere 2018 ¹⁹ AbsZambiaFacility fast trackDec 2016-Jan 2017n=6 FGD with patients and professional HCW n=8 IDIs with other HCWJere 2018 ¹⁹ AbsTanzaniaClinic and home based adherence interventionAug 2015-Feb 2016n=438 patientsMcCoy 2017 ³¹ ArtSouth AfricaFacility fast trackJan-Sept 2017 Nov 2016-Feb 2017n=31 patientsObunga 2018 ³² AbsSouth AfricaFast track initiation distributionNov 2016-Feb 2017 Nov 2016-Feb 2017n=613 patientsHE ² RO and BU 2017 ¹⁰ Rep 2017 ¹⁰ Out of facility based individual models(OFBIM) registered patientsKatchy 2018 ¹⁷ AbsNigeriaCommunity ART distributionNot indicated registered patientsRoberts 2018 ¹⁰ AbsSouth AfricaMobile ART care for FSWsNov 2016-Feb 2017 refn=631 (cost data for n=84)HE ² RO 2017 ¹⁰ RepSouth AfricaMobile ART care for registered patientsNov 2016-Feb 2017 registered patientsGeldsetzer 2018 ⁸ AbsSouth Af	Malawi		Feb-May 2016		Prust 2017 ⁷	Article
NigeriaMulti-month scriptingJan-Oct 2017n=49,680 patientsAttah 2018 ¹⁵ AbsNigeriaMulti-month scriptingOct-Dec 2017n=15 KII with HCW n=6 FGD with patients. Total n<48	Malawi		Feb-May 2016	n=30 FGDs with 216	Prust 2018 ¹³	Article
NigeriaMulti-month scriptingOct-Dec 2017n=15 KII with HCW n=6 FGD with patients. Total ns48Katchy 2018 ¹⁴ AbsZambiaFacility fast trackDec 2016-Jan 2017n=6 FGD with patients and professional HCW n=8 IDIs with other HCWJere 2018 ¹⁹ AbsTanzaniaClinic and home based adherence interventionAug 2015-Feb 2016n=438 patientsMcCoy 2017 ³¹ ArtKenyaFacility fast trackJan-Sept 2017n=3,110 patientsObunga 2018 ³² AbsSouth AfricaFast track initiation counselling; early patient tracingNov 2016-Feb 2017n=631 patientsHE ² RO and BU 2017 ¹⁰ RegOut of facility based individual models(OFEIM)n=6 FGD with patients rotal ns48Katchy 2018 ¹⁷ AbsSouth AfricaCentral chronic medicine dispensing and distributionNot indicated registered patientsn=2,000,000 active registered patientsRoberts 2018 ¹¹ PreSouth AfricaDecentralized medication deliveryNov 2016-Feb 2017 n=24 FSWn=631 (cost data for n=84)HE ² RO 2017 ¹⁰ RegSouth AfricaCentral chronic medication deliveryNov 2016-Feb 2017 n=24 FSWn=631 (cost data for n=84)HE ² RO 2017 ¹⁰ RegSouth AfricaDecentralized medication deliveryNov 2016-Feb 2017 n=24 FSWn=631 (cost data for n=84)HE ² RO 2017 ¹⁰ RegSouth AfricaDecentralized medication deliveryNov 2016-Feb 2017 n=2172 patientsn=631 (cost data for n=84)HE ² RO 2017 ¹⁰ RegTanzan	Malawi	Multi-month scripting	Nov 2016-Feb 2017		(ICAP Interval	Present
n=6 FGD with patients. Total ns48n=6 FGD with patients. Total ns48ZambiaFacility fast trackDec 2016-Jan 2017 n=6 FGDs with other HCW n=8 IDIs with other HCW n=8 IDIs with other HCW n=8 IDIs with other HCW n=8 IDIs with other HCW n=438 patientsJere 2018 ¹⁹ Abs and professional HCW n=8 IDIs with other HCW n=8 IDIs with other HCW n=8 IDIs with other HCWAct Act Act Aug 2015-Feb 2016n=438 patientsMcCoy 2017 ³¹ Art Act McCoy 2017 ³¹ Art Act Act Act ActKenyaFacility fast trackJan-Sept 2017 Nov 2016-Feb 2017 ourseling; early patient tracingn=5110 patients n=631 patients n=631 patients n=66D with patients rotal ns48McCoy 2017 ³¹ Act Act Act Act Act ActAct ActAct Act	Nigeria	Multi-month scripting	Jan-Oct 2017	n=49,680 patients	Attah 201815	Abstrac
and professional HCW n=8 IDIs with other HCWTanzaniaClinic and home based adherence interventionAug 2015-Feb 2016n=438 patientsMcCoy 2017 ³¹ ArtKenyaFacility fast trackJan-Sept 2017n=3,110 patientsObunga 2018 ³² AbsSouth AfricaFast track initiation counselling; early patient tracingNov 2016-Feb 2017n=631 patientsHE ² RO and BU 2017 ¹⁰ Rep 2017 ¹⁰ Out of facility based individual models (OFBIM)Nov 2016-Feb 2017n=15 KII with HCWs n=6 FGD with patients Total n≤48Katchy 2018 ¹⁷ AbsNigeriaCommunity ART distributionOct-Dec 2017 n=0 tradicine dispensing and distributionNot indicated n=2,000,000 active registered patientsRoberts 2018 ¹¹ PreSouth AfricaMobile ART care for FSWsSept-Nov 2017 Nov 2016-Feb 2017n=631 (cost data for n=84)HE ² RO 2017 ¹⁰ AbsSouth AfricaDecentralized medication deliveryNov 2016-Feb 2017 n=24 FSWn=631 (cost data for n=84)HE ² RO 2017 ¹⁰ RepTanzaniaARV community deliveryMar 2016-Oct 2017 n=2,172 patientsFrancis 2017 ³⁶ AbsTanzaniaARV community deliveryMar 2016-Jan 2017 n=334 patientsFrancis 2017 ³⁶ AbsUgandaCommunity ARTNov-Dec 2016 ARTn=604 patientsSemitala 2018 ³⁷ Abs	Nigeria	Multi-month scripting	Oct-Dec 2017	n=6 FGD with patients.	Katchy 2018 ¹⁴	Abstract
based adherence interventionJan-Sept 2017n=3,110 patientsObunga 2018 ³² AbsKenyaFacility fast trackJan-Sept 2017n=3,110 patientsObunga 2018 ³² AbsSouth AfricaFast track initiation counselling; early patient tracingNov 2016-Feb 2017n=631 patientsHE ² RO and BU 2017 ¹⁰ Rep 2017 ¹⁰ Out of facility based individual models (OFBIM)Nov 2016-Feb 2017 n=15 KII with HCWs n=6 FGD with patients Total n≤48Katchy 2018 ¹⁷ AbsNigeriaCommunity ART distributionOct-Dec 2017 n=0 fGD with patients Total n≤48Roberts 2018 ¹¹ Pre registered patientsSouth AfricaCentral chronic medicine dispensing and distributionNot indicated sept-Nov 2017n=24 FSWComins 2018 ²⁰ AbsSouth AfricaDecentralized medication deliveryNov 2016-Feb 2017 Nov 2016-Feb 2017n=631 (cost data for n=84)HE ² RO 2017 ¹⁰ RepTanzaniaARV community deliveryMar 2016-Oct 2017 n=334 patientsn=334 patientsFrancis 2017 ³⁶ AbsUgandaCommunity-based ARTNov-Dec 2016n=604 patientsSemitala 2018 ³⁷ AbsUgandaCommunityNov 2016-Septn=8,820 patientsSuu 2018 ¹² Pre	Zambia	Facility fast track	Dec 2016-Jan 2017	and professional HCW	Jere 2018 ¹⁹	Abstrac
South Africa South Africa Fast track initiation counselling; early patient tracingNov 2016-Feb 2017n=631 patientsHE ² RO and BU 2017 ¹⁰ RegOut of facility based individual models(OFBIM)Nov 2016-Feb 2017n=15 KII with HCWs n=6 FGD with patients Total ns48Katchy 2018 ¹⁷ AbsNigeriaCommunity ART distributionOct-Dec 2017 n=15 KII with HCWs n=6 FGD with patients Total ns48Katchy 2018 ¹⁷ AbsSouth Africa South AfricaCentral chronic medicine dispensing and distributionNot indicated n=2,000,000 active registered patientsRoberts 2018 ¹¹ PreSouth Africa Bouth AfricaMobile ART care for FSWsSept-Nov 2017 n=24 FSWn=631 (cost data for n=84)HE ² RO 2017 ¹⁰ RegSouth Africa deliveryNov 2016-Feb 2017 medication deliveryn=2,172 patientsGeldsetzer 2018 ⁸ ArtTanzania deliveryARV community deliveryMar 2016-Oct 2017 n=334 patientsFrancis 2017 ³⁶ AbsUganda (Damunity-based ARTNov-Dec 2016 Nov 2016-Septn=604 patientsSemitala 2018 ³⁷ AbsUgandaCommunity Nov 2016-Septn=8,820 patientsSuuna 2018 ¹² Pre	Tanzania	based adherence	Aug 2015-Feb 2016	n=438 patients	McCoy 2017 ³¹	Article
counselling; early patient tracing201710Out of facility based individual models (OFBIM)NigeriaCommunity ART distributionOct-Dec 2017 and distributionn=15 KII with HCWs n=6 FGD with patients Total n≤48Katchy 201817 AbsAbsSouth AfricaCentral chronic medicine dispensing and distributionNot indicated sept-Nov 2017n=2,000,000 active registered patientsRoberts 201811 Pre registered patientsPreSouth AfricaMobile ART care for FSWsSept-Nov 2017 Nov 2016-Feb 2017n=24 FSWComins 201820 AbsAbsSouth AfricaDecentralized medication deliveryNov 2016-Feb 2017 Nar 2016-Oct 2017n=631 (cost data for n=84) n=631 (cost data for n=84)HE²RO 201710 RegRegTanzaniaARV community deliveryMar 2016-Oct 2017 Nar 2016-Jan 2017n=334 patientsFrancis 201736 Semitala 201837AbsUgandaCommunity-based ARTNov-Dec 2016 Nov 2016-Septn=604 patientsSemitala 201837 Suna 201812Pre	Kenya	Facility fast track	Jan-Sept 2017	n=3,110 patients	Obunga 2018 ³²	Abstrac
Out of facility based individual models (OFBIM)NigeriaCommunity ART distributionOct-Dec 2017 n=6 FGD with patients Total n≤48Katchy 201817AbsSouth AfricaCentral chronic medicine dispensing and distributionNot indicated sept-Nov 2017n=2,000,000 active registered patientsRoberts 201811PreSouth AfricaMobile ART care for FSWsSept-Nov 2017 medication deliveryn=24 FSWComins 201820AbsSouth AfricaDecentralized medication deliveryNov 2016-Feb 2017 medication deliveryn=631 (cost data for n=84)HE²RO 201710 HE²RO 201710RegTanzaniaARV community deliveryMar 2016-Oct 2017 medication deliveryn=334 patientsFrancis 201736 AbsAbsUgandaCommunity-based ARTNov-Dec 2016 Nov 2016-Septn=604 patientsSemitala 201837 AbsAbs	South Africa	counselling; early	Nov 2016-Feb 2017	n=631 patients		Report
NigeriaCommunity ART distributionOct-Dec 2017n=15 KII with HCWs n=6 FGD with patients Total n≤48Katchy 201817AbsSouth AfricaCentral chronic medicine dispensing and distributionNot indicated n= 2,000,000 active registered patientsRoberts 201811PreSouth AfricaCentral chronic medicine dispensing and distributionNot indicated sept-Nov 2017n=24 FSWComins 201820AbsSouth AfricaMobile ART care for FSWsSept-Nov 2017n=631 (cost data for n=84)HE2RO 201710RegSouth AfricaDecentralized medication deliveryMar 2016-Oct 2017n=2,172 patientsGeldsetzer 20188ArtTanzaniaARV community deliveryMar 2016-Jan 2017n=334 patientsFrancis 201736AbsUgandaCommunity-based ARTNov-Dec 2016 Nov 2016-Septn=604 patientsSeuitala 201837AbsUgandaCommunityNov 2016-Septn=8,820 patientsSsuua 201812Pre	Out of facility	· ÷	; (OFBIM)			
medicine dispensing and distributionregistered patientsSouth AfricaMobile ART care for FSWsSept-Nov 2017 n=24 FSWn=24 FSWComins 2018 ²⁰ AbsSouth AfricaDecentralized medication deliveryNov 2016-Feb 2017 n=631 (cost data for n=84)HE ² RO 2017 ¹⁰ RegTanzaniaARV community deliveryMar 2016-Oct 2017 n=2,172 patientsGeldsetzer 2018 ⁸ ArtTanzaniaARV community deliveryMar 2016-Jan 2017 n=334 patientsFrancis 2017 ³⁶ AbsUgandaCommunity-based ARTNov-Dec 2016 Nov 2016-Septn=604 patientsSemitala 2018 ³⁷ AbsUgandaCommunityNov 2016-Septn=8,820 patientsSuuna 2018 ¹² Pre		Community ART		n=6 FGD with patients	Katchy 2018 ¹⁷	Abstract
FSWsSouth AfricaDecentralized medication deliveryNov 2016-Feb 2017 n=631 (cost data for n=84)HE²RO 2017¹0 HE²RO 2017¹0Rep RepTanzaniaARV community deliveryMar 2016-Oct 2017 n=2,172 patientsn=2,172 patientsGeldsetzer 20188 nectorArt deliveryTanzaniaARV community deliveryMar 2016-Jan 2017 n=334 patientsn=334 patientsFrancis 2017³6 nectorAbs deliveryUgandaCommunity-based ARTNov-Dec 2016 Nov 2016-Septn=604 patientsSemitala 2018³7 nectorAbs deliveryUgandaCommunityNov 2016-Septn=8,820 patientsSsuura 2018¹2Pre	South Africa	medicine dispensing	Not indicated		Roberts 2018 ¹¹	Present
medication deliveryMar 2016-Oct 2017n=2,172 patientsGeldsetzer 20188ArtTanzaniaARV community deliveryMar 2016-Jan 2017n=334 patientsFrancis 2017 ³⁶ AbsTanzaniaARV community deliveryMar 2016-Jan 2017n=334 patientsFrancis 2017 ³⁶ AbsUgandaCommunity-based ARTNov-Dec 2016n=604 patientsSemitala 2018 ³⁷ AbsUgandaCommunityNov 2016-Septn=8,820 patientsSsuuna 2018 ¹² Pre	South Africa		Sept-Nov 2017	n=24 FSW	Comins 2018 ²⁰	Abstrac
deliveryTanzaniaARV community deliveryMar 2016-Jan 2017 n=334 patientsn=334 patientsFrancis 2017 ³⁶ AbsUgandaCommunity-based ARTNov-Dec 2016 n=604 patientsn=604 patientsSemitala 2018 ³⁷ AbsUgandaCommunityNov 2016-Septn=8,820 patientsSsuuna 2018 ¹² Pre	South Africa		Nov 2016-Feb 2017	n=631 (cost data for n=84)	HE ² RO 2017 ¹⁰	Report
delivery Uganda Community-based Nov-Dec 2016 n=604 patients Semitala 2018 ³⁷ Abs ART Uganda Community Nov 2016-Sept n=8,820 patients Ssuuna 2018 ¹² Pre	Tanzania	•	Mar 2016-Oct 2017	n=2,172 patients	Geldsetzer 2018 ⁸	Article
ART Uganda Community Nov 2016-Sept n=8,820 patients Ssuuna 2018 ¹² Pre	Tanzania	•	Mar 2016-Jan 2017	n=334 patients	Francis 2017 ³⁶	Abstrac
	Uganda	•	Nov-Dec 2016	n=604 patients	Semitala 2018 ³⁷	Abstrac
pharmacies 2018	Uganda	Community pharmacies	Nov 2016-Sept 2018	n=8,820 patients	Ssuuna 2018 ¹²	Present
Zambia Home-based delivery May-Dec 2017 n=874 patients Limbada 2018 ³⁸ Abs	Zambia	Home-based delivery	May-Dec 2017	n=874 patients	Limbada 2018 ³⁸	Abstrac

Country	Model name	Dates of data collection	Sample size	Author	Туре
Mozambique	Community pharmacies	Oct-Nov 2017	n=406 patients	Maranga 2018 ³⁵	Abstract
Ghana	Community based care for FSW and MSM	Jan-March 2018	n=38 KPs	Benefour 2018 ³⁴	Abstract
Healthcare we	orker led groups (HCWLG	i)			
South Africa	Community based adherence clubs	Aug 7-Nov 2017	n=59 patients; n=20 HCW	Meehan 2018 ²¹	Abstract
South Africa	Post-partum adherence clubs	Jul-Sept 2016	n=19 patients; n=9 HCWs	Trafford 2018 ²²	Article
South Africa	Adherence clubs	Nov 2016-Feb 2017	n=631 (cost data for n=57)	HE ² RO 2017 ¹⁰	Report
South Africa	Adherence clubs	Nov 2016-Feb 2017	n=2,092patients	Berrada 2019 (CaSIPO) ²⁸	Present.
South Africa	Youth care clubs	Aug 2016-Dec 2017	n=589 patients	Beery 2018 ⁹	Abstract
Zambia	Urban adherence groups	Mar-Jul 2016	n= 15 FGD with patients, family members and HCW n= 18 IDI with government officials and local leaders	Mwamba 2018 ²⁴	Abstract
Zambia	Community adherence groups	May 2016-Oct 2017	n=603 patients	Roy 2017 ²⁷	Abstract
Zambia	Urban adherence groups	May 2016-Oct 2017	n=1,096 patients	Roy 2018 ²³	Abstract
Zambia	Adherence clubs	May-Dec 2017	n=868 patients	Limbada 2018 ³⁸	Abstract
Tanzania	Expert client peer support	Not indicated	N.S	MOH Tanzania,2017 ²⁵	Report
Client led grou	ups (CLG)				
Malawi	Community ART groups	Feb-May 2016	n=714 observations of visit time and flow	Prust 2017 ⁷	Article
Malawi	Community ART groups	Feb-May 2016	n=32 interviews with HCW; n=30 FGDs with 216 patients	Prust 2018 ¹³	Article
Nigeria	Client managed groups	Oct-Dec 2017	n=15 KII with HCWs; n=6 FGD with patients; Total n ≤48	Katchy 2018 ¹⁴	Abstract
Zimbabwe	Community ART refill groups	Oct-Dec 2017	n=20KII from provider; n= 155 CARG participants in n=20 FGDs	Mashungu 2018 ²⁹	Abstract
Kenya	Community-based ART groups	Jan-Sept 2017	n=3,110 patients	Obunga 2018 ³²	Abstract
Zambia	Community adherence groups	Not indicated	n=1,035 patients	Mwamba 2018 (CIDRZ) ³⁰	Present.

FGD – Focus group discussions KII – Key informant Interviews

IDI – In-depth interviews

HCWs – Healthcare workers